Tenofovir Disoproxil Fumarate Tablets 300 mg, manufactured and marketed by Kureasia Pharma, are a high-quality antiretroviral medication designed to provide effective and reliable treatment for HIV-1 infection and chronic hepatitis B virus (HBV) infection. Each film-coated tablet contains Tenofovir Disoproxil Fumarate equivalent to 300 mg of Tenofovir, formulated with precision to ensure optimal bioavailability, consistent therapeutic action, and patient safety.
Tenofovir Disoproxil Fumarate belongs to the pharmacological class of nucleotide reverse transcriptase inhibitors (NRTIs). It works by blocking the activity of the reverse transcriptase enzyme, which is essential for viral replication. By inhibiting this enzyme, Tenofovir helps to prevent the virus from multiplying and reduces the viral load in the body. This leads to an improvement in immune function and a decrease in the progression of HIV infection, thereby enhancing the quality of life for patients.
In patients with chronic hepatitis B, Tenofovir Disoproxil Fumarate helps to lower the amount of HBV in the bloodstream, improving liver enzyme levels and reducing liver damage. Regular use under medical supervision can help slow the progression of liver disease and reduce complications such as cirrhosis or liver cancer.
Kureasia Pharma’s Tenofovir Disoproxil Fumarate Tablets are produced under strict international quality standards, following Good Manufacturing Practices (GMP) to ensure purity, stability, and consistency in every batch. The formulation is designed for once-daily oral administration, providing convenience and enhancing treatment adherence for long-term therapy. Each tablet is carefully coated to facilitate easy swallowing and to minimize gastrointestinal discomfort.
Tenofovir Disoproxil Fumarate 300 mg is often prescribed as part of combination antiretroviral therapy (ART) with other antiretroviral agents. This combination approach enhances viral suppression, reduces the likelihood of resistance development, and improves overall treatment efficacy.
Key Benefits:
Potent and selective inhibition of HIV-1 and HBV replication.
Proven long-term efficacy and safety profile.
Enhances immune recovery and delays disease progression.
Reduces the risk of HIV transmission when used consistently as prescribed.
Supports liver health in chronic hepatitis B patients.
Storage and Handling:
Store the tablets below 30°C, in a dry place, away from direct sunlight and moisture. Keep the medicine out of reach of children.
Kureasia Pharma is committed to delivering affordable, accessible, and effective healthcare solutions that meet the highest global standards. Through scientific innovation and a dedication to excellence, Kureasia Pharma aims to improve treatment outcomes and quality of life for patients worldwide.
With Tenofovir Disoproxil Fumarate Tablets 300 mg, Kureasia Pharma continues its mission of advancing healthcare through reliable formulations that combine therapeutic efficacy, safety, and patient comfort—empowering medical professionals and patients in the fight against HIV and hepatitis B